Eric Kmiec

Company: CorriXR Therapeutics

Job title: Founder, Chief Executive & Scientific Officer

Seminars:

Refining Preclinical Regulations: Clarifying Requirements for Safety, Efficacy, and Pharmacological Evidence to Establish the Regulatory Gold Standard & Minimize Uncertainty in Clinical Translation 1:00 pm - 4:00 pm

As the in vivo cell engineering and gene editing space rapidly develops, leaving uncertainties in regulatory requirements, this workshop delves into considerations for effective model selection and strategies for producing comprehensive safety and efficacy evidence to effectively prepare for treatment evaluation and approval from regulatory boards.Read more

day: Pre-Conference Workshop

Shaping the Next Generation of In Vivo Gene Editing 3:45 pm

Explore cutting-edge technologies improving the accuracy and efficiency of in vivo genetic editing techniques, such as CRISPR and base editing Address the evolving methods to enhance delivery systems, ensuring targeted and efficient gene editing in diverse tissues and organs Delving into metabolism changes as a result of in vivo gene editing Sharing preclinical successesRead more

day: Day Two